Key result
Updated 2023 Australian CVD algorithm reclassifies fewer adults high-risk, yielding an ~8-point absolute reduction.
Why the study?
How does the 2023 Australian CVD risk algorithm change 5-year CVD risk distribution and high/intermediate/low risk categorisation compared with the 2012 algorithm in a primary care population without existing CVD?
Observational (n=115,873)
Yes
How does the 2023 Australian CVD risk algorithm change 5-year CVD risk distribution and high/intermediate/low risk categorisation compared with the 2012 algorithm in a primary care population without existing CVD?
Answers are grounded in this paper and cite their sources.
Implementing the 2023 Australian CVD risk guidelines reduces the proportion of primary care patients automatically classified as high risk from 17.6% to 9.7% while more than doubling the intermediate-risk group (from 11.6% to 26.4%), highlighting the critical importance of clinician-led risk reclassification and shared decision-making for intermediate-risk individuals.
Objectives To quantify cardiovascular disease (CVD) risk, and implications for targeting preventive pharmacotherapy, using the 2023 guideline‐recommended Australian CVD risk algorithm, and compare this to the previous (2012) algorithm. Study Type Application and comparison of two risk prediction algorithms. Setting and Participants Data from 115,873 people aged 45–74 years without existing CVD, who had a clinical encounter between September 2020 and August 2022, recorded within MedicineInsight, a longitudinal primary care database covering 8% of Australian general practices. Main Outcome Measures CVD risk distribution and risk categorisation into low‐, intermediate‐ and high‐risk groups under the 2023 and 2012 algorithms. Cohen's kappa and Bland–Altman plots were used to assess agreement and concordance. Results Using the 2023 CVD risk algorithm and revised thresholds, 9.7% of participants were at high CVD risk (≥ 10% 5‐year risk or clinically determined high risk); 26.4% were at intermediate CVD risk (5% to < 10% 5‐year risk) and 63.9% were at low CVD risk (< 5% 5‐year risk). Corresponding 2012 figures for CVD risk were 17.6% high (> 15% 5‐year risk or clinically determined high risk), 11.6% intermediate (10%–15% 5‐year risk) and 70.8% low (< 10% 5‐year risk). Differences in proportions at high risk were largely driven by changes to clinically determined criteria for high risk. Overall, there was moderate‐to‐substantial agreement (linear‐weighted kappa = 0.62) and concordance (Kendall's tau‐ b = 0.74) between algorithms. Conclusion Proportions estimated at low risk and not routinely recommended pharmacotherapy align with international standards and were similar between guidelines. Although fewer people would be recommended pharmacotherapy due to being high risk under the updated versus previous guidelines, this likely reflects more accurate updated CVD risk estimation for the contemporary Australian population. The 2023 guidelines include a discretionary step (untested in our study) allowing adjustment based on additional factors. To ensure continued reduction of CVD burden across the population, we emphasise the use of this reclassification step by clinicians and consideration of the benefits of pharmacotherapy for those at intermediate risk.
No takes yet. Share an insight, caveat, or question.
Lazarevic et al. (2026) conducted an observational in Primary prevention of cardiovascular disease (people without existing CVD) (n=115,873). 2023 Australian CVD risk algorithm (AUS-PREDICT and AUS-T2D-PREDICT) vs. 2012 Australian CVD risk algorithm (Framingham-based) was evaluated on Proportion of participants classified as at high 5-year CVD risk and risk classification agreement between the 2023 and 2012 algorithms (Linear-weighted kappa 0.62, 95% CI 0.61-0.62). The 2023 Australian CVD risk algorithm classified 9.7% of primary care adults as high risk compared to 17.6% under the 2012 algorithm.
Synapse has enriched 10 related papers. Consider them for comparative context: